Related Experiment Video
Updated: Jan 23, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Advances in management of giant cell arteritis
Ian Liang1,2, Hugh Caterson1,2, Anthony Sammel1,2
1Department of Rheumatology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Insights
Giant cell arteritis (GCA) management involves prompt glucocorticoid initiation and newer therapies like tocilizumab to reduce steroid side effects. Long-term strategies for GCA are individualized, balancing efficacy with patient factors.
Area of Science:
- Rheumatology
- Internal Medicine
- Vasculitis
Background:
- Giant cell arteritis (GCA) is a critical systemic vasculitis affecting older adults.
- It poses risks of vision loss, stroke, and aortic complications.
Purpose of the Study:
- To review current best practices for GCA management in Australia.
- To highlight recent therapeutic advancements and long-term care strategies.
Main Methods:
- Review of current literature and clinical guidelines.
- Focus on therapeutic advances and complication management.
- Consideration of individualized treatment beyond 12 months.
Main Results:
- Glucocorticoids are central to acute GCA management.
- Tocilizumab has shown efficacy in reducing glucocorticoid-related morbidity within 12 months.
- Upadacitinib demonstrates recent therapeutic promise.
Conclusions:
- Optimal GCA treatment beyond 12 months requires individualized approaches.
- Management must address disease and treatment-related complications.
- This review provides a framework for current Australian GCA care.
Abstract:
Giant cell arteritis (GCA) is the most common systemic vasculitis in older adults and is a medical emergency due to the potential for irreversible visual loss and stroke in the acute phase and aortic complications in the longer term. Prompt recognition of the condition and immediate initiation of glucocorticoids remain central to management and advances in therapy, particularly with tocilizumab in the first 12 months, have reduced glucocorticoid-related morbidity. Upadacitinib has recently been shown in phase 3 trials to be effective, and its place in the Australasian therapeutic landscape will evolve in the coming years. Management also focusses on assessing for and reducing disease and treatment-related complications, including relapse, aortic aneurysm, infection, diabetes and osteoporosis. The optimal treatment strategy beyond the initial 12 months of therapy remains undefined and is typically individualised and informed by comorbidities, patient preference, clinician familiarity, cost and regulatory access. This review outlines current best practice for the management of GCA in Australia with a focus on recent therapeutic advances and strategies for longer-term patient care.
Related Concept Videos
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Extraction: Advanced Methods
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Impression Management Techniques I: Managing Appearances
Tonsillitis II: Management
Management of Insomnia

